A Phase 2 randomized, double-blind, placebo-controlled study to investigate efficacy, safety, immunogenicity, and pharmacokinetics, of GSK3862995B in participants with bronchiectasis

Trial status: Authorised 1. Annualized rate of exacerbationsa, 2. Time to first exacerbation, 3. Annualized rate of severe exacerbations What is the percentage reduction in annualized exacerbation rate on GSK3862995B versus placebo, in adult patients with bronchiectasis and recurrent exacerbations or uncontrolled symptoms assuming no study treatment discontinuation occurred, change in maintenance SOC or use of prohibited medications.

1. Annualized rate of exacerbationsa, 2. Time to first exacerbation, 3. Annualized rate of severe exacerbations

Age group: 65+ years, 18-64 years Gender: Female, Male Target enrollment: 207 participants